[go: up one dir, main page]

WO2002023784A3 - Cysteine protease inhibitors - Google Patents

Cysteine protease inhibitors Download PDF

Info

Publication number
WO2002023784A3
WO2002023784A3 PCT/US2001/028714 US0128714W WO0223784A3 WO 2002023784 A3 WO2002023784 A3 WO 2002023784A3 US 0128714 W US0128714 W US 0128714W WO 0223784 A3 WO0223784 A3 WO 0223784A3
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine protease
protease inhibitors
compounds
formula
diseases associated
Prior art date
Application number
PCT/US2001/028714
Other languages
French (fr)
Other versions
WO2002023784A2 (en
Inventor
James T Palmer
Bernard L Hirschbein
Original Assignee
Axys Pharm Inc
James T Palmer
Bernard L Hirschbein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc, James T Palmer, Bernard L Hirschbein filed Critical Axys Pharm Inc
Priority to AU2001296247A priority Critical patent/AU2001296247A1/en
Publication of WO2002023784A2 publication Critical patent/WO2002023784A2/en
Publication of WO2002023784A3 publication Critical patent/WO2002023784A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds, compositions and methods for treating diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsins B, K, L or S.The present invention thus provides compounds of Formula (I): pharmaceutical compositions comprising compounds of Formula (I) and methods of treating diseases associated with cysteine protease activity using pharmaceutical compositions comprising compounds of Formula (I).
PCT/US2001/028714 2000-09-12 2001-09-11 Cysteine protease inhibitors WO2002023784A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001296247A AU2001296247A1 (en) 2000-09-12 2001-09-11 Cysteine protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23178700P 2000-09-12 2000-09-12
US60/231,787 2000-09-12

Publications (2)

Publication Number Publication Date
WO2002023784A2 WO2002023784A2 (en) 2002-03-21
WO2002023784A3 true WO2002023784A3 (en) 2002-05-16

Family

ID=22870646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028714 WO2002023784A2 (en) 2000-09-12 2001-09-11 Cysteine protease inhibitors

Country Status (2)

Country Link
AU (1) AU2001296247A1 (en)
WO (1) WO2002023784A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156063A1 (en) * 2001-04-06 2002-10-24 Setti Eduardo L. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051998A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
WO2001044214A1 (en) * 1999-12-03 2001-06-21 Ono Pharmaceutical Co., Ltd. Oxadiazole derivatives and drugs containing these derivatives as the active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051998A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
WO2001044214A1 (en) * 1999-12-03 2001-06-21 Ono Pharmaceutical Co., Ltd. Oxadiazole derivatives and drugs containing these derivatives as the active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200153, Derwent World Patents Index; Class B02, AN 2001-488551, XP002192288 *

Also Published As

Publication number Publication date
WO2002023784A2 (en) 2002-03-21
AU2001296247A1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
AU2003243095A1 (en) New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
YU17402A (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
WO2003041649A3 (en) Cyanoalkylamino derivatives as protease inhibitors
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
WO2002008198A3 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
IS7925A (en) Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
WO2004112701A3 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
GB0112348D0 (en) Compounds
SE0201980D0 (en) Novel compounds
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005028429A3 (en) Haloalkyl containing compounds as cysteine protease inhibitors
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
YU87202A (en) Arylmethylamine derivatives for use as tryptase inhibitors
DK1532124T3 (en) Use of nitride derivatives as a drug
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
MXPA04005809A (en) Protein kinase inhibitors.
WO2003099202A3 (en) Beta-secretase inhibitors
WO2002051848A3 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
MXPA03001455A (en) Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity.
AU2003303076A1 (en) Cathepsin cysteine protease inhibitors and their use
WO2004056832A3 (en) Epothilone derivatives
WO2004060878A3 (en) Inhibitors of phosphatases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP